Windfall Week for Trial Data: Papers on Crenezumab, Neflamapimod, Tofersen
Three drugs, targeting three different pathogenic mechanisms in Alzheimer's, dementia with Lewy bodies, and ALS, had trial data formally published this week.
NEWS
Can 10,000 Steps a Day Keep Dementia at Bay?
Adults who hit this number were half as likely as their sedentary peers to develop dementia over seven years. Power walking for 30 minutes daily cut risk by 60 percent.
As Health Problems Pile Up, Dementia Climbs on Top of the Heap
According to findings from more than 200,000 people 60 and older, having multiple chronic diseases nearly doubles the risk of dementia within the next 12 years.
Pseudotime Simulates Disease Progression from Case-Control RNA-Seq
Aligning single-cell gene expression in “pseudotime” models longitudinal change. It explores how healthy cells become sick during Alzheimer's.
Meta-Analysis of RNA-Seq Data is Robust, Finds Key Changes in AD
By pooling single-nucleus RNA-sequencing datasets, scientists found consistent changes across Alzheimer’s cohorts. Examples: hypermetabolic transcription, and a new neuron population that dies early on.
RNA-Seq from 2.8 Million Cells Yields New Clues About Alzheimer's
Analysis identified neuronal populations that die early in AD and glial subtypes that expand. Gliosis signaled fast memory decline.
RIKEN Says Its Mouse Models Are Now Easier to Obtain
Fewer requirements and simpler agreements should improve accessibility, use.
Scientists Say It's Time to Update ATN Criteria
In this classification scheme, T, i.e. tau, means different things. Phospho-tau predicts tangle buildup, whereas tau-PET signals neurodegeneration and cognitive decline.
SPOTLIGHT
Can 10,000 Steps a Day Keep Dementia at Bay?
Time to lace up those sneakers. Adults who power-walked 30 minutes per day slashed their dementia risk over the next seven years by 60 percent. A daily step count of 9,800 halved the odds. Walking just 3,800 steps per day edged down the risk of dementia by 25 percent.
Pseudotime Simulates Disease Progression from Case-Control RNA-Seq
Scientists use pseudotime analysis to grapple with massive RNA-sequencing datasets. This algorithm orders cells into a tree-like form based on the similarity of their expression, exposing sequential gene expression changes. At AAIC, scientists showed how this works. Some followed transcriptomic change in astrocytes, finding a continuum of homeostatic to reactive cells. Others plotted entire prefrontal cortex transcriptomes onto pseudotime trees, or tied transcriptomic pseudotime to metabolomic change in the Alzheimer’s brain.
Meta-Analysis of RNA-Seq Data is Robust, Finds Key Changes in AD
Guided by gene-expression data from new biopsy tissue, a “meta-analysis” of sorts of pooled, older snRNA-Seq databases has enabled researchers to grow statistical power. This type of cumulative analysis of progressively growing datasets marks a sea change in single-cell transcriptomics in Alzheimer's research. An analysis presented at AAIC uncovered common transcriptional changes throughout Alzheimer’s disease progression. Inhibitory neurons perish early on in the cortex, accompanied by a hypermetabolic transcriptional phenotype in excitatory neurons.
RNA-Seq from 2.8 Million Cells Yields New Clues About Alzheimer’s
A first analysis of two of the largest single-nucleus RNA-sequencing efforts in Alzheimer’s disease—each encompassing more than 1 million cells—revealed neuronal subpopulations that died early in AD, showed a subsequent rise in glial numbers, and tied gliosis to rapid memory decline in a subset of participants. Also, do microglia get riled up earlier than astrocytes?
Join The Conversation
Professional Resources
New in last 7 days
-
Grants
- New Items: 6
- Total Items: 525
-
Jobs
- Total Items: 55
-
Conference Calendar
- New Items: 3
- Total Items: 121
- Member Directory
Latest Comments